Search results
Results from the WOW.Com Content Network
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology .
The company is forging ahead with next-generation drug development solutions.
Things have gotten so bad for biotech company Ginkgo Bioworks Holdings (NYSE: DNA) that it recently had to do a 1-for-40 reverse stock split to keep its share price up and stay listed on the New ...
Sadly, Ginkgo Bioworks' businesses aren't growing these days. They're shrinking at a frightening pace. Diagnostics or "Biosecurity" sales collapsed by 71% year over year to just $10 million.
In July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal. [29] On October 3, 2023, Zymergen filed for Chapter 11 bankruptcy. [30] On February 5, 2024, Zymergen announced that it would liquidate after selling all of its remaining assets and employee layoffs. [31]
Ginkgo Bioworks has become a penny stock -- and that's the least of its problems, Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst Skip to main content
Agapakis is now the Creative Director of the Boston-based biotechnology company Ginkgo Bioworks, known as "The Organism Company," which specializes in genetically engineering organisms like yeast and bacteria for a number of applications—from engineering perfumes and food to engineering solutions for more sustainable agriculture.
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $2.78, marking a +0.72% move from the previous day.